Clostridioides difficile is ubiquitous, anaerobic bacteria that survives unfavorable conditions by forming spores. It is the most common hospital pathogen thus representing a major problem for healthcare systems in many countries. Clinical manifestations can range in severity from minimal, self-limited diarrhea to severe fulminant colitis. Lately, there have been several epidemic outbreaks across the world caused by hypervirulent C. difficile strains that not only increase morbidity and mortality rates, but also lead to a higher recurrence rate. Recurrent infections occur in approximately 25% patients following initial episode and its rates increase with every new recurrent episode. Many risk factors are associated with recurrence, some of the most important being repeated antibiotic use, increased age of the patient and infection with hypervirulent strains. A timely diagnosis is required in order to choose the right therapy. At the same time, choosing the therapeutic protocol depends on the infection being the initial episode or (and which number of) recurrent episode. Oral vancomycin and fidaxomicin have shown the greatest success in the treatment of recurrent C. difficile infections, while fecal microbiota transplantation remains recommended therapy option for multiple recurrences. There are many promising therapeutic options regarding reduction of recurrence rates, with monoclonal antibody bezlotoxumab being one of them. However further studies are being required. Since recurrent infections represent extreme healthcare burden for the country, it is important to recognize and reduce the impact of recurrence risk factors, as well as apply adequate preventive measures, in order to reduce the negative effect of these infections to the minimum.